Fudan University professor found that new mechanisms for regulation of gene activity are expected to dampen | | inhibition of carcinogenesis carcinogenesis genetic mechanisms _ news
Original title: Fudan University Professor finds new mechanism of gene regulation, is expected to inhibit cancer
In the Green online Shanghai April 7 electric (China Youth reported ? in the Green online reporter Ye Wang Czech) in cancer cells in the, chromatin in the of enhanced child runaway will excessive strengthened near cancer gene of activity, led to cell exception even cancer; but meanwhile, appeared in the regional of protein RACK7 and to methyl of enzyme KDM5C can limit this class enhanced child of activity, makes gene expression keep in normal range, to inhibit cancer.
This is the Biomedical Research Institute of Fudan University (IBS) Professor LAN Fei laboratory and Shi Yang-Shi Yujiang professors lab, a new discovery. On April 7, the new findings are published in one of the world's most authoritative academic journals on the Cell.
? Youth online reporter of China Youth daily, which found the equivalent of finding a gene regulating the activity of "switch", the switch can control the gene change faster or slower. Research Group found a protein called RACK7, it can attract histone methyltransferase called KDM5C, the original high methylation into low methylation status, making around it remain within the normal range of gene expression and tissue cells cancerous. However, this new discovery will become a real cancer drugs, there is still a long way to go.
Major international projects for basic research and Chief Scientist, researcher Chen degui introduction to our current research and development of new drugs, the drugs if you want to launch, you need at least 15 years, "in China, it is difficult to find one willing to invest 15 years of an innovative new drugs. ”
Chen degui said that the birth of a new drug to go through complex of preclinical studies and at least 3 of the clinical research, Professor blue Fiji's newly discovered, currently in the design phase only, not in preclinical studies, "China business, few people are willing to put in the preclinical studies, they are more like investing after the clinical. ”
In fact, cancer is not controlled, but anticancer drugs from research and development to production time too long. "Scientists find targets, creates a target for drugs against a form of cancer, can have 50 to 100 drugs to choose from using, cancer may not be terrible. "LAN Fei said RACK7 and KDM5C in the risk of breast cancer, such as lung cancer tumor, at present, the laboratory in his attempts to research new medicines," if companies are to invest, optimistic 5 years should be products. ”
In recent years, Professor, school of life sciences, Fudan University, Yang will have independent intellectual property rights, IDO inhibitors for cancer immunotherapy with the $ 65 million price paid license to United States HUYA company. The incident sparked widespread discussions in the community, of which about "why not sell to pharmaceutical companies in China" sound of most.
LAN Fei said that his new-found will also face similar problems in the future, "our vision, willing to wait for 5 to 15 years too little long-term return on investment of enterprises, drug companies understand research reveals new professionals rarely, afraid to vote, those who won't vote majority. More pharmaceutical companies rather than spend more money from abroad to ask foreign companies to buy back later clinical ' insurance ', which, in front of the clinic, is most likely Chinese scientists discover new drugs to sell. ”
Responsible editor: Liu Debin SN222
Article keywords:Inhibition mechanism of cancer genes
I want feedback
Save a Web page
China Youth daily
复旦教授发现基因活性调控新机制 有望抑制癌变|抑制癌变|基因机制_新闻资讯
原标题：复旦教授发现基因活性调控新机制，有望抑制癌变
中青在线上海4月7日电（中国青年报·中青在线记者 王烨捷）在癌细胞中，染色质中的增强子失控会过度强化附近癌基因的活性，导致细胞异常甚至癌变；但与此同时，出现在该区域的蛋白质RACK7和去甲基化酶KDM5C可以限制此类增强子的活性，使基因表达保持在正常范围，从而抑制癌变。
这是复旦大学生物医学研究院（IBS）蓝斐教授实验室和施扬教授-石雨江教授实验室的一项最新发现。4月7日，这一新发现被刊登在全世界最权威的学术杂志之一《Cell》上。
中国青年报·中青在线记者了解到，这项发现相当于找到了一种基因活性的调控“开关”，这个开关，可以控制基因变化得快一些或者是慢一些。研究组找到了一种名为RACK7的蛋白质，它可以吸引名为KDM5C的组蛋白去甲基化酶，将原本的高甲基化状态转化成低甲基化状态，使得其周围的基因表达保持在正常范围，从而组织细胞癌变。但，这一新发现要变成一种真正的抗癌药物的话，还有很长一段路要走。
国际重大基础研究专项项目首席科学家、研究员陈德桂介绍，以我国目前的新药研发现状，这一药物如果要推出，至少需要15年时间，“中国企业中，很难找到愿意投资15年获得一项创新型新药的。”
陈德桂说，一种新药的诞生，要经过复杂的临床前研究和临床后至少3期的研究，蓝斐等教授的新发现，目前仅仅处于研发阶段，尚未进入临床前研究，“中国的企业，几乎很少有人愿意在临床前研究上进行投入的，他们更多地喜欢在临床后进行投入。”
实际上，癌症并非不能控制，只是抗癌药物从研发到出产的时间过于漫长。“科学家通过发现靶点，创造生产针对这一靶点的药物，如果针对一种癌症，能有50种到100种药物可以挑选使用，癌症或许就没有那么可怕了。”蓝斐说，RACK7和KDM5C容易出现在乳腺癌、肺癌等肿瘤病灶中，目前，实验室也在自己尝试根据研究试制新药，“如果有企业来投入，乐观估计5年时间应该可以出产品。”
就在不久前，复旦大学生命科学学院教授杨青将具有自主知识产权、用于肿瘤免疫治疗的IDO抑制剂以6500万美元的价格有偿许可给美国HUYA公司。这一事件曾引发社会广泛讨论，其中有关“为何不卖给中国药企”的声音最甚。
蓝斐说，他的新发现未来同样会面临相似的问题，“我国有眼光、愿意等待5年至15年长期投资回报的企业太少，药企里看得懂科研新发现的专业人士也很少，不敢投、不愿投的人居多。更多的药企，宁可从国外花更多的钱问国外企业买回临床后期的’保险产品’，而这些产品，在临床前，很有可能就是中国科学家发现新药物卖出去的。”
责任编辑：刘德宾 SN222
文章关键词： 抑制癌变 基因机制
我要反馈
保存网页
中国青年报